Pleuropulmonary changes induced by ergoline drugs

European Respiratory Journal

Volumn 9, Issue 5, 1996, Pages 1013-1019

  Pfitzenmeyer, P ^a   Foucher, P ^a   Dennewald, G ^b   Chevalon, B ^c   Debieuvre, D ^d   Bensa, P ^a   Piard, F ^a   Camus, P ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b CENTRE CARDIOLOGIQUE DU NORD   (France)

^c Centre Hospitalier de LENS   (France)

^d Centre Hospitalier Paul Morel   (France)

Author keywords

Drug induced adverse effects in lung; drug induced adverse pleural reaction; ergoline; ergot; pleural thickening; pleurisy

Indexed keywords

BROMOCRIPTINE; DEFLUINA; DIHYDROERGOCRISTINE; DIHYDROERGOTAMINE; ERGOLINE DERIVATIVE; ERGOTAMINE; METHYSERGIDE; NICERGOLINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; LUNG LAVAGE; MALE; PLEURA DISEASE; PLEURA EFFUSION; PLEURA THICKENING; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BRONCHOALVEOLAR LAVAGE; ERGOLINES; FEMALE; HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PLEURAL DISEASES; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0029982714     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.96.09051013     Document Type: Article

References (46)

1. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Part 2. Noncytotoxic drugs. Am Rev Respir Dis 1986; 133: 488-505.
2. De Vriese ASP, Philippe J, van Renterghem DM, et al. Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature. Medicine (Baltimore) 1995; 74: 144-150.
3. Graham JR, Suby HI, LeCompte PR, Sadowsky NL. Fibrotic disorders associated with methysergide therapy for headache. N Engl J Med 1966; 274: 359-368.
4. Graham JR. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci 1967; 254: 1-12.
5. Bays RP. Pleuropulmonary fibrosis following therapy with methysergide maleate: two case reports. J LA State Med Soc 1968; 120: 426-427.
6. Lindeneg O, Kok-Jensen A. Pleuritis og pleural fibrose opstaet under behandling med metysergid. Nord Med 1968; 79: 681-684.
7. Hindle W, Posner E, Sweetnam MT, Tan RSH. Pleural effusion and fibrosis during treatment with methysergide. Br Med J 1970; 1: 605-606.
8. Kok-Jensen A, Lindeneg O. Pleurisy and fibrosis of the pleura during methysergide treatment of hemicrania. Scand J Respir Dis 1970; 51: 218-222.
9. Dunn JM, Sloan H. Pleural effusion and fibrosis secondary to sansert administration. Ann Thorac Surg 1973; 15: 295-298.
10. Akoun GM, Herson S, Huchon G, Marsac JH. Fibrose pleuro-pulmonaire au methysergide avec complexes immuns circulants. Nouv Presse Med 1975; 4: 2809.
11. Meeran MK, Ahmed AH, Parsons FM, Anderson CK. Constrictive pericarditis due to methysergide therapy. S Afr Med J 1976; 50: 1595-1597.
12. Gefter WB, Epstein DM, Bonavita JA, Miller WT. Pleural thickening caused by sansert and ergotartrate in the treatment of migraine. Am J Roentgenol 1980; 135: 375-380.
13. Lambard J, Vincent J, Roge JM, Akoun G, Michel PL. Fibrose pleuro-pulmonaire au methysergide. Nouv Presse Med 1981; 10: 2440-2441.
14. Hansen G, Abildgaard U, Skarpass IJK. Alvorlige bivirkninger av methysergid. T Norske Laegeforen 1986; 106: 2160-2166.
15. Muller R, Weller P, Chemaissani A. Pleurafibrose als Nebenwirkung einer langjahrigen Methysergid-Therapie. Dtsch Med Wschr 1991; 116: 1433-1436.
16. Sherrick AD, Brown LR, Harms GF, Myers JL. The radiographic findings of fibrosing mediastinitis. Chest 1994; 106: 484-489.
17. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease. Lancet 1981; i: 44.
18. Le Witt PA, Calne DB. Recent advances in the treatment of Parkinson's disease: the role of bromocriptine. J Neurol Transm 1981; 51: 175-184.
19. Bottcher AJ, Gron U. Pleuropulmonale forandringer ved bromokriptinbehandling af parkinsonisme. Ugeskr Laeger 1981; 143: 2648-2649.
20. Besser GM, Wass JAH. Pleuropulmonary shadows on bromocriptine. Lancet 1981; i: 323.
21. Krupp P. Pleuropulmonary changes during long-term bromocriptine. Lancet 1981; i: 44.
22. Vergeret J, Barat M, Taytard A, et al. Fibrose pleuropulmonaire et bromocriptine. Sem Hôp Paris 1984; 60: 741-744.
23. Douvier JJ, Vergeret J, Taytard A, et al. La bromocriptine dans la maladie de Parkinson: toxicité pleuropulmonaire. Ann Med Interne 1985; 136: 416-418.
24. Tornling G, Unge G, Axelsonn G, Noring L, Granerus AK. Pleuropulmonary reactions in patients on bromocriptine treatment. Eur J Respir Dis 1986; 68: 35-38.
25. Mouysset B, Montastruc JL, Rostin M, et al. Bromocriptine et fibrose pleuro-pulmonaire. Therapie 1986; 41: 73-75.
26. Wiggins J, Skinner C. Bromocriptine-induced pleuropulmonary fibrosis. Thorax 1986; 41: 328-330.
27. Ward CD. Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment. Lancet 1987; i: 1706-1707.
28. McElvaney NG, Wilcox PG, Churg A, Fleetham JA. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988; 148: 2231-2226.
29. Kinnunen E, Viljanen A. Pleuropulmonary involvement during bromocriptine treatment. Chest 1988; 94: 1034-1036.
30. Diot E, Diot P, Le Rolland A, Joinville AP, et al. Epanchements pleuraux induits par la bromocriptine. Rev Mal Respir 1990; 7: 175-177.
31. Hely MA, Morris GJL, Lawrence S, Jeremy R, Genge S. Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy. Aust NZ J Med 1991; 21: 82-84.
32. Schmid PA, Suter T, Speich R, Eberli F, Greminger P. Bromocriptin-induzierte Pleuropneumopathie. Dtsch Med Wschr 1994; 119: 1543-1546.
33. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991; 30: 613-616.
34. Frans E, Dom R, Demedts M. Pulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992; 5: 263-265.
35. Ibsen KK, Lindeneg O. Ergotaminbehandling og pleuritis. Ugeskr Laeg 1979; 141: 860.
36. Taal BG, Spierings ELH, Hilvering C. Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine. Thorax 1983; 38: 396-398.
37. Robert M, Derbaudrenghien JP. Fibrotic processes associated with long-term ergotamine therapy. N Engl J Med 1984; 311: 601.
38. Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J. Pleural and retroperitoneal fibrosis from dihydroergotamine. N Engl J Med 1989; 321: 1760.
39. Zijlstra EE, Wilson JHP, Ouwendijk RJTh. Pleural fibrosis associated with ergotamine therapy. Eur J Intern Med 1990; 1: 245-247.
40. Allen MB, Tosh G, Walters G, Muers MF. Pleural and pericardial fibrosis after ergotamine therapy. Respir Med 1994; 88: 67-69.
41. Camus Ph, Gibson GJ. Adverse pulmonary effects of drugs and radiation. In: Brewis RAL, Corrin B, Geddes DM, Gibson G, eds. Respiratory Medicine. Philadelphia, WB Saunders, 1995; pp. 630-657.
42. Miller DH, Haas LF. Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene. J Neurol Neurosurg Psychiatr 1984; 47: 553-554.
43. Moss SF, Lehner PJ, Gilbey SG, et al. Pleural involvement in the carcinoid syndrome. QJ Med 1993; 86: 49-53.
44. Jiménez-Jiménez FJ, Lopez-Alvarez J, Sanchez-Chapado M, et al. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Clin Neuropharmacol 1995; 18: 277-290.
45. Seaton A. Pleural and pericardial fibrosis after ergotamine therapy. Respir Med 1994; 88: 480.
46. Lombard JN, Bonnette B, Maynadié M, et al. Celiprolol pneumonitis. Eur Respir J 1993; 9: 588-591.